Submitted by PharmaGossip Blog
The chief executive of Merck has told Reuters that negative media coverage of the ENHANCE trial of the company’s blockbuster Vytorin cholesterol drug has unfairly overlooked benefits of the medicine.
Subscribe in a reader
Our research department goes to great lengths to discover bloggers who possess creative, informative and entertaining qualities and to then present these bloggers to you, with their respective links, on the 1800blogger platform. We encourage our readers to click on these links to learn more about the blogger and their writings.